Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Author: Global Cancer Consortium
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.
For many breast cancer patients, the effects of undergoing a mastectomy go well beyond the physical.
Advances in medicine have allowed people in developed countries to live longer, but at a cost: An increased lifespan raises a patient’s likelihood of developing health issues such as angina or incontinence.
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
The Newton, Mass.-based biopharmaceutical company is developing a small-molecule drug for sickle cell disease.
The San Diego-based company seeks to improve upon existing cancer therapeutics with its reformulations of the chemotherapy drugs Navelbine and Taxotere.